Raloxifene (Evista) for Osteoporosis: Bone Protection & Breast Cancer Benefit

Raloxifene (brand name Evista) is a daily oral medication for osteoporosis that belongs to a class called SERMs (Selective Estrogen Receptor Modulators). It acts like estrogen in bone (reducing bone breakdown) and unlike estrogen in the breast and uterus (where it blocks estrogen receptors). This makes it useful for postmenopausal women who need bone protection but cannot take estrogen. A unique benefit: it also reduces the risk of invasive breast cancer by about 44%.

Raloxifene reduces vertebral fracture risk by about 30–55% depending on baseline fracture status. However, it has NOT been shown to reduce hip fracture risk in randomized trials — a notable difference from bisphosphonates and other options. This makes it better suited for patients with predominant vertebral osteoporosis risk rather than hip fracture risk.

Yes — this is an important safety consideration. Raloxifene increases the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) by approximately 3-fold, similar to the risk seen with estrogen. It should not be used in patients with a personal history of blood clots, prolonged immobility, or other major clot risk factors. Your endocrinologist will review your complete clotting history before prescribing.

Yes. Raloxifene reduces the risk of invasive estrogen receptor-positive breast cancer by approximately 44% in postmenopausal women — equivalent to tamoxifen in reduction of breast cancer risk, with a better safety profile. For postmenopausal women with both osteoporosis and elevated breast cancer risk (by family history, dense breasts, or BRCA status), raloxifene may address two goals simultaneously. This dual benefit should be discussed with your endocrinologist and any relevant specialists.

Raloxifene is best for postmenopausal women with osteoporosis who predominantly have vertebral fracture risk (rather than hip), who also have elevated breast cancer risk or want the breast cancer prevention benefit, who cannot tolerate bisphosphonates, and who do not have a history of blood clots or significant clot risk factors. It is not appropriate as the primary therapy for women with high hip fracture risk.

Raloxifene is generally not combined with other antiresorptive medications for osteoporosis (Prolia, bisphosphonates) as there is typically no additive benefit. It may be used sequentially — for example, after completing anabolic therapy (Forteo, Tymlos, Evenity). Your endocrinologist will determine the appropriate role of raloxifene in your overall treatment plan.